Growth Hormone Secretagogue Peptides

Growth hormone secretagogue peptides are a family of research compounds that stimulate the somatotropic (growth hormone) axis through defined receptor pathways. They fall into two broad mechanistic classes investigated in laboratory settings: growth hormone-releasing hormone (GHRH) analogs, which act on the GHRH receptor, and ghrelin mimetics — also called growth hormone secretagogue receptor (GHS-R1a) agonists — which act on a distinct receptor. This hub explains the GH/IGF-1 axis and maps the individual peptides most frequently examined in preclinical and in-vitro research, linking to detailed guides on each.

Research Use Only. All peptides and compounds discussed here are intended strictly for laboratory, in-vitro, and preclinical research use only. They are not for human or veterinary use, are not intended to diagnose, treat, cure, or prevent any disease, and have not been evaluated by the FDA. Nothing in this article is medical advice or a dosing protocol. Descriptions refer to mechanisms and findings reported in scientific studies and research models.

The GH/IGF-1 Axis: Why Secretagogues Matter in Research

Growth hormone (GH) is synthesized and released by somatotroph cells in the anterior pituitary. Its secretion is governed by a two-signal system originating in the hypothalamus. GHRH provides the primary stimulatory drive, while somatostatin (SRIF) provides tonic inhibition. Layered on top is ghrelin, a stomach-derived peptide hormone that acts as an endogenous ligand for GHS-R1a and amplifies GH release. Once secreted, GH acts on peripheral tissues — chiefly the liver — to stimulate production of insulin-like growth factor 1 (IGF-1), the principal mediator of many downstream anabolic and metabolic effects. IGF-1, in turn, exerts negative feedback on both the hypothalamus and pituitary.

A defining feature of this axis is that GH is released in pulses, not continuously. This pulsatility is physiologically important, and it is a central reason researchers distinguish between secretagogues that preserve pulsatile release and those that produce more sustained elevation. For a complete mechanistic walkthrough of these signaling relationships, see the GHRH & Growth Hormone Axis mechanism guide.

Class 1: GHRH Analogs

GHRH analogs are synthetic peptides modeled on the native GHRH sequence (or its bioactive 1-29 fragment, sometimes called sermorelin). They bind the GHRH receptor on somatotrophs and stimulate GH synthesis and release in a manner that research suggests preserves the natural pulsatile pattern. Native GHRH is degraded rapidly by the enzyme dipeptidyl peptidase-4 (DPP-4), so a major theme in this class is structural modification to extend half-life.

CJC-1295

CJC-1295 is a GHRH analog studied in two distinct forms. The version with DAC (Drug Affinity Complex) incorporates a maleimide group that binds covalently to serum albumin, dramatically extending its circulating half-life in research models. The version without DAC — often referred to as modified GRF(1-29) — lacks this albumin-binding moiety and acts over a much shorter window. These pharmacokinetic differences are the entire point of comparison in the literature. Explore the details in the CJC-1295 with DAC research guide and the head-to-head CJC-1295 with vs without DAC comparison.

Tesamorelin

Tesamorelin is a stabilized GHRH analog carrying an N-terminal modification that confers resistance to enzymatic degradation. In research contexts it is notable for the specific metabolic pathways it has been used to investigate. See the Tesamorelin research guide for its mechanism and study history, and the Tesamorelin vs CJC-1295 comparison for how two GHRH analogs differ in structure and reported behavior.

Class 2: Ghrelin Mimetics (GHS-R1a Agonists)

Ghrelin mimetics act on a different receptor entirely — the growth hormone secretagogue receptor (GHS-R1a) — mimicking the endogenous action of ghrelin. Rather than replicating the GHRH signal, they add a complementary stimulatory input and, in some research models, suppress somatostatin tone. Because their receptor target is distinct from that of GHRH analogs, this class is central to studies of synergistic co-stimulation.

Ipamorelin

Ipamorelin is one of the most studied ghrelin mimetics in research, valued in the literature for its selectivity: preclinical studies characterize it as stimulating GH release through GHS-R1a with minimal reported effect on other pituitary hormones such as cortisol or prolactin, distinguishing it from earlier, less selective secretagogues. The Ipamorelin research guide covers this selectivity profile in depth.

The Synergy Model: GHRH + Ghrelin

Because GHRH analogs and ghrelin mimetics act on separate receptors and separate arms of the regulatory system, research has repeatedly examined their combination. Studies have reported that co-administration of a GHRH agonist with a GHS-R1a agonist can produce a greater GH response than either signal alone — a supra-additive or synergistic effect thought to arise from simultaneous GHRH-receptor stimulation and somatostatin suppression. This is the mechanistic rationale behind the widely studied pairing of CJC-1295 and Ipamorelin. Read more in the GHRH + Ghrelin synergy guide, and see how the two individual peptides compare in the Ipamorelin vs CJC-1295 research comparison.

Downstream: IGF-1 and the Effector End of the Axis

Secretagogues act upstream, prompting the pituitary to release the body's own GH. IGF-1 sits at the downstream, effector end of the axis. IGF-1 LR3 is a long-acting analog of IGF-1 (Long R3 IGF-1) engineered with an arginine substitution and an N-terminal extension that reduce binding to IGF binding proteins, extending its activity in research models. Because it introduces the effector molecule directly rather than stimulating endogenous release, IGF-1 LR3 represents a mechanistically opposite research tool to the secretagogues. Compare the two approaches in IGF-1 LR3 vs GH secretagogues, review the compound itself in the IGF-1 LR3 research guide, and see sourcing considerations in where to buy IGF-1 LR3 research peptide (USA).

Laboratory Handling of Research Preparations

These peptides are supplied as lyophilized (freeze-dried) powder for laboratory use. As general handling guidance for research preparations: lyophilized peptide is typically stored frozen and protected from light until reconstitution. For in-vitro work, researchers commonly reconstitute with bacteriostatic or sterile water added slowly against the vial wall, swirling rather than shaking to avoid shearing the peptide. Reconstituted solutions are generally kept refrigerated and used within the working window established by the researcher's own stability data. All NeuroLabs research peptides are ≥99% purity and third-party COA-tested, with a certificate of analysis available for each lot.

Choosing a Research Compound: A Quick Map

Selecting between these in a research design depends on the mechanistic question — whether the aim is to stimulate pulsatile endogenous GH (GHRH analogs), add a complementary ghrelin-pathway signal (ghrelin mimetics), probe synergy (combinations), or study effector-level IGF-1 activity directly. The linked cluster guides address each pathway in the depth a research protocol requires.

Reminder: every compound referenced is for laboratory research use only — not for human or veterinary use, not evaluated by the FDA, and not intended to diagnose, treat, cure, or prevent any disease. To request a certificate of analysis or place a research order, contact neurolabsresearch3@gmail.com.